TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03735173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ReUnion TSA, pegged design
Description: ReUnion total shoulder arthroplasty system, pegged design

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ReUnion TSA, pegged design
Description: ReUnion total shoulder arthroplasty system, pegged design

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ReUnion TSA, keeled design
Description: ReUnion total shoulder arthroplasty system, keeled design

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ReUnion TSA, keeled design
Description: ReUnion total shoulder arthroplasty system, keeled design
Study: NCT03959228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: keto-analogs
Description: The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
Study: NCT02113839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Before re-breathing (if the patient not performed one 6 months in advance).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Before re-breathing (if the patient not performed one 6 months in advance).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO Exhaled breath
Description: In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO Exhaled breath
Description: In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: P01
Description: P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
Study: NCT04408209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Convalescent Plasma - early treatment of patients with severe COVID-19. Clinical and laboratory data of patients will be collected before initiation of the procedure, 30 minutes after the first dose, 30 minutes after the second dose and 30 minutes after the third plasma dose and then on days 1-7, 14, 21, 28, 35 from the start of treatment. In case of adverse reactions during transfusion such as acute shortness of breath, haemodynamic instability or high pre-existing and non-disease-related fever, the transfusion will be interrupted and detailed recording of the event as well as updating the Adverse Events Management Committee will be performed.~In addition to the standard assessments, the titer of neutralizing anti-SARS-CoV-2 antibodies will be measured in a sample drawn prior to plasmapheresis.~All donors will be tested for:~1. the titer of IgG anti-SARS-CoV-2 antibodies (Pasteur Institute)~2. the titer of neutralizing anti-SARS-CoV-2 antibodies (Pasteur Institute)
Study: NCT03606590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L(P) device
Description: Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
Study: NCT02113839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: P01
Description: P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
Study: NCT03004183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADV/HSV-tk
Description: Replication-defective recombinant adenovirus vector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Prodrug of the antiviral drug acyclovir

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Low-dose SBRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
Study: NCT04487730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage & Connect Psychotherapy
Description: 9-weeks of weekly psychotherapy sessions focused on social reward exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Review and Psychoeducation (SRP)
Description: 9-weeks of weekly psychotherapy sessions focused on symptom review and psychoeducation about depression and aging
Study: NCT04953169

Intervention type: OTHER
Group type: OTHER
Intervention: Biobank Video
Description: The video describes the process of biobanking with visuals

Intervention type: OTHER
Group type: OTHER
Intervention: Non-Video
Description: The non-video group will receive a written informed consent
Study: NCT04098744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate vaginal insert
Description: Artesunate formulated as vaginal inserts, 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal insert
Description: Placebo for artesunate vaginal inserts
Study: NCT02169401

Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium Neurostimulator
Study: NCT00178659

Intervention type: OTHER
Intervention: Blood/saliva samples for protein/molecular analysis
Description: Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)

Intervention type: OTHER
Intervention: Blood/saliva samples for protein/molecular analysis
Description: Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)

Intervention type: OTHER
Intervention: Blood/saliva samples for protein/molecular analysis
Description: Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)

Intervention type: OTHER
Intervention: Blood/saliva samples for protein/molecular analysis
Description: Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
Study: NCT03681093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fevipiprant 150 mg
Description: Fevipiprant (QAW039) 150 mg once daily administered orally as tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fevipiprant 450 mg
Description: Fevipiprant (QAW039) 450 mg once daily administered orally as tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily administered orally as tablet
Study: NCT03471910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin
Description: Diosmin 600mg tablet, once daily
Study: NCT03342794

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
Study: NCT04359680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for six weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super B-Complex
Description: Vitamin Super B-Complex administered orally twice daily to maintain the blind
Study: NCT00409227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha blocker-alfuzosin
Description: P.O. alfuzosin 10 mg once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once a day for 3 months or stone free
Study: NCT03931785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-7246
Description: Oral tablet
Study: NCT03471910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin / Hesperidin
Description: Diosmin 900 mg / Hesperidin 100mg tablet, once daily
Study: NCT03931785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-7246
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD-7246
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablet
Study: NCT02113839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FeNO
Description: The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FeNO
Description: The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
Study: NCT01404065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
Study: NCT04356703

Intervention type: OTHER
Intervention: Neuropsicomotor developmental test
Description: Children will be evaluated trough Bayley III and PEDI scale. They also will be examined by pediatrician, neurosurgeon, orthopedics and phisiatry
Study: NCT01573728

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low dose exercise
Description: Exercise totaling 50 minutes per week and low intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Health Exercise
Description: At least 150 minutes at moderate intensity
Study: NCT02914678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
Study: NCT01652105

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard diet versus standard VLCD (Prodimed)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet versus standard VLCD (Prodimed)
Study: NCT03546374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Ablation
Description: In addition to the concomitant surgery, subjects are required to have amputation or closure (with sutures or ligation) of the left atrial appendage.The Cox Maze IV lesion set is required to be performed.
Study: NCT03540498

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AB-DENTALAC [Probiotics (study)]
Description: Treatment for 6 weeks, which will consist of the consumption of a chewing gum AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5E+8 CFU each at the end of shelf life), b.i.d (morning and evening).
Study: NCT03546374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioblate and Cryoflex hand held devices
Description: The Cardioblate hand held devices consist of the Cardioblate iRF and Cryo surgical ablation devices.
Study: NCT04340869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theobromine
Description: Natural extract from Cocoa

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theobromine
Description: Natural extract from Cocoa

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remin Pro
Description: Remin Pro

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remin Pro
Description: Remin Pro
Study: NCT00463970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Description: Physical examination, education and follow up by a physiotherapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 7 sessions of CBT over a period of 2 months, included a booster session after 3 months
Study: NCT03540498

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (control)
Description: Treatment for 6 weeks, which will consist of the consumption of a chewing gum placebo, without probiotics strains, b.i.d (morning and evening).
Study: NCT00463970

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seal oil
Description: 20 capsules per day for 3 months
Study: NCT03249220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of the CBMS Probe
Description: Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
Study: NCT02102971

Intervention type: PROCEDURE
Intervention: Hepatocellular carcinoma
Description: Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
Study: NCT04551391

Intervention type: OTHER
Intervention: Blood and urine sampling
Description: Retinal OCT is a novel, non-invasive method for cross-sectionally imaging the eye's retina and choroid
Study: NCT00463970

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy oil
Description: 20 capsules per day for 3 months
Study: NCT00642811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
Study: NCT04217447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAC + Aspirin 100mg od
Description: Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OAC + placebo of Aspirin 100mg od
Description: Patients will receive full-dose of OAC + placebo of Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
Study: NCT01293526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control
Description: Patients who respond will have leads will be placed using standard procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Patients who respond will have their leads placed based on study measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental 2
Description: Patients who respond will have their leads placed based on standard lead placement.
Study: NCT00642811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: (over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
Study: NCT02131220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prourokinase
Description: 20mg intracoronary bolus infusion using selective catheter during PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: 10ug/kg intracoronary bolus infusion using selective catheter during PCI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: intracoronary bolus infusion using selective catheter during PCI
Study: NCT01225510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856884
Description: PF-04856884 at a dose of 15 mg/kg/week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04856884
Description: PF-04856884 at a dose of 15 mg/kg/week
Study: NCT04403035

Intervention type: DIAGNOSTIC_TEST
Intervention: ID NOW vs. Accula
Description: Comparison of the ID Now assay vs. the Accula assay in detecting Covid-19.
Study: NCT04031690

Intervention type: OTHER
Intervention: Caregiver Quality of Life Questionnaires
Description: Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
Study: NCT03259971

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic-Lactobacillus plantarum PS128
Description: Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
Study: NCT03259971

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic-Lactobacillus plantarum PS128
Description: Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
Study: NCT01757691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg/daily
Study: NCT01742962

Intervention type: PROCEDURE
Intervention: Radical prostatectomy for prostate cancer
Description: Prior treatment with open or robot assisted laparoscopic prostatectomy.
Study: NCT01595646

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline, administered intranasally twice per day for a 16 week duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Description: 20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: 20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
Study: NCT00878228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
Study: NCT01845025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol 12 mcg
Description: Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 mcg
Description: Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100 mcg
Description: Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 mcg
Description: Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250 mcg
Description: Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg
Description: Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 500 mcg
Description: Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match formoterol one inhalation twice daily via dry powder inhaler
Study: NCT02760602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV
Study: NCT00703807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
Study: NCT01580475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training - detraining - retraining
Description: Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).